Tyra Biosciences, Inc. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 9th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • New York
INDEMNIFICATION AGREEMENTIndemnification Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”), and , [a member of the Board of Directors/ an officer] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement.
TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is entered into this 16th day of January, 2020 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Ronald Swanson (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
TYRA BIOSCIENCES, INC. Common Stock (par value $0.0001 per share) ATM Sales AgreementAtm Sales Agreement • October 3rd, 2022 • Tyra Biosciences, Inc. • Pharmaceutical preparations • New York
Tyra Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Virtu Americas LLC (the “Agent”) as follows:
TYRA BIOSCIENCES, INC. SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Second Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Todd Harris (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO”) of its common stock (the “Effective Date”). In the event the IPO does not occur, this Agreement shall be of no force or effect and the Prior Agreement shall continue. Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • August 20th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of March, 2021, by and among Tyra Biosciences, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
TYRA BIOSCIENCES, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 5th, 2024 • Tyra Biosciences, Inc. • Pharmaceutical preparations • New York
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of February 1, 2024 (the “Effective Date”), by and between TYRA BIOSCIENCES, INC., a Delaware corporation (the “Company”), and each of the purchasers whose names and addresses are set forth on Schedule A hereto (each, a “Purchaser” and, collectively, the “Purchasers”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 9th, 2021 • Tyra Biosciences, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of March, 2021, by and among Tyra Biosciences, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • November 7th, 2024 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is effective as of September 9, 2024 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Douglas Warner, M.D. (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
FIRST AMENDMENT TO LEASELease • March 22nd, 2023 • Tyra Biosciences, Inc. • Pharmaceutical preparations
This First Amendment to Lease (this “Amendment”) is made and entered into as of May 16, 2022, by and between Fabric 2676 State Street, LLC, a California limited liability company (“Lessor”), and TYRA Biosciences, Inc., a Delaware corporation (“Lessee”).
TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • March 3rd, 2022 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is entered into as of August 19, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and John Healy (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO”) of its common stock (the “Effective Date”). In the event the IPO does not occur, this Agreement shall be of no force or effect. Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
THIRD AMENDMENT TO LEASELease • March 19th, 2024 • Tyra Biosciences, Inc. • Pharmaceutical preparations
This Third Amendment to Lease (this “Amendment”) is made and entered into as of March 18, 2024, by and between Fabric 2676 State Street, LLC, a California limited liability company (“Lessor”), and TYRA Biosciences, Inc., a Delaware corporation (“Lessee”).
CONSULTING AGREEMENTConsulting Agreement • March 22nd, 2023 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (the “Agreement”) is effective as of January 1, 2023 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”), and Esther van den Boom (“Advisor”).
TYRA BIOSCIENCES, INC. TRANSITION AGREEMENTTransition Agreement • November 7th, 2024 • Tyra Biosciences, Inc. • Pharmaceutical preparations • California
This Transition Agreement (the “Agreement”) is entered into effective as of August 3, 2024 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Hiroomi Tada, M.D., Ph.D. (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwise defined shall have those meanings set forth in Appendix I hereto.
SECOND AMENDMENT TO LEASELease • March 22nd, 2023 • Tyra Biosciences, Inc. • Pharmaceutical preparations
This Second Amendment to Lease (this “Amendment”) is made and entered into as of January 6, 2023, by and between Fabric 2676 State Street, LLC, a California limited liability company (“Lessor”), and TYRA Biosciences, Inc., a Delaware corporation (“Lessee”).
FIRST AMENDMENT TO LEASELease • March 3rd, 2022 • Tyra Biosciences, Inc. • Pharmaceutical preparations
This First Amendment to Lease (this “Amendment”) is made and entered into as of March 2, 2022, by and between Fabric 2656 State, LLC, a California limited liability company (“Lessor”), and TYRA Biosciences, Inc., a Delaware corporation (“Lessee”).
SECOND AMENDMENT TO LEASELease • March 22nd, 2023 • Tyra Biosciences, Inc. • Pharmaceutical preparations
This Second Amendment to Lease (this “Amendment”) is made and entered into as of December 20, 2022, by and between Fabric 2656 State, LLC, a California limited liability company (“Lessor”), and TYRA Biosciences, Inc., a Delaware corporation (“Lessee”).
